A Phase I / Pilot Study of Intra-Arterial Supradose Cisplatin With Simultaneous Intravenous Thiosulfate Neutralization in Patients With Primary Lung Cancer or Lung Metastases

Inclusion Criteria:

- Primary lung cancer (any type) or dominant lung metastases from other primary
cancers.

- Patients must have either measurable or evaluable disease.

- Karnofsky performance status ≥ 70%.

- Greater than 18 years of age.

- Life expectancy > 3 months.

- 3 week elapse from previous cytotoxic therapy (except for erlotinib or hormonal
therapy, which can be ongoing) with side effects improved to grade 2 or less, and no
prior radiotherapy to the lung.

- Adequate organ function.

- Treated brain metastases, if present, with toxicities improved to grade 2 or less.

- Willingness and ability to sign a written informed consent.

Exclusion Criteria:

- Prior radiation to the largest lesion in the lung.

- Current pregnancy or breast-feeding.

- Unwillingness or inability to practice contraception.

- Renal insufficiency.

- Comorbidities of grade 3 or greater.

- Concurrent medical or psychiatric conditions as defined by the treating physician
which would preclude safe performance of study procedures or compromise the ability
of the patient to consent to study.